Pseudomonas aeruginosa is an opportunistic human pathogen for which new antimicrobial drug options are urgently sought. P. aeruginosa disulfide-bond protein A1 (PaDsbA1) plays a pivotal role in catalyzing the oxidative folding of multiple virulence proteins and as such holds great promise as a drug target. As part of a fragment-based lead discovery approach to PaDsbA1 inhibitor development, the identification of a crystal form of PaDsbA1 that was more suitable for fragment-soaking experiments was sought. A previously identified crystallization condition for this protein was unsuitable, as in this crystal form of PaDsbA1 the active-site surface loops are engaged in the crystal packing, occluding access to the target site. A single residue involved in crystal-packing interactions was substituted with an amino acid commonly found at this position in closely related enzymes, and this variant was successfully used to generate a new crystal form of PaDsbA1 in which the active-site surface is more accessible for soaking experiments. The PaDsbA1 variant displays identical redox character and in vitro activity to wild-type PaDsbA1 and is structurally highly similar. Two crystal structures of the PaDsbA1 variant were determined in complex with small molecules bound to the protein active site. These small molecules (MES, glycerol and ethylene glycol) were derived from the crystallization or cryoprotectant solutions and provide a proof of principle that the reported crystal form will be amenable to co-crystallization and soaking with small molecules designed to target the protein active-site surface.
Introduction
Disulfide-bond (DSB) proteins are bacterial oxidoreductase enzymes that catalyze the folding of disulfide bonds in unfolded or partially folded protein substrates. The primary oxidase is DsbA, which typically employs a Cys-Xaa-Xaa-Cys (CXXC) active-site motif to catalyze a series of thiol-exchange reactions that ultimately oxidize reduced protein substrates. DsbA is itself maintained in an active state by interactions with a partner redox membrane protein (DsbB). DsbA substrates include many structural and secreted virulence effector proteins, and there is now overwhelming evidence that the DSB machinery plays a vital role in the pathogenicity of Proteobacteria ; deletion of DsbA prevents lethal bacterial infection in vivo and has pleiotropic effects upon virulence (Ireland et al., 2014; Totsika et al., 2009 al., 2001). As a consequence of its role in the activity of multiple downstream effector proteins, P. aeruginosa DsbA (PaDsbA1) is a promising target for inhibition and hence novel antimicrobial development. Fragment-based lead discovery (FBLD) approaches offer an efficient way to identify small-molecule binders that can subsequently be elaborated or linked to generate eventual drug-like compounds (Erlanson, 2012) . Indeed, the approach has recently led to the design of early-stage inhibitors of Escherichia coli DsbA (Adams et al., 2015) . Highly advantageous for the iterative progression from hit to lead in such an FBLD campaign is high-resolution structural information about target-compound interactions to inform rational medicinal chemistry efforts.
The crystal structure of PaDsbA1 has previously been determined to 1.5 Å resolution (Shouldice et al., 2010) . However, inspection of the crystal packing revealed that a network of interactions, in particular a salt bridge, engages the active-site surface in a tightly packed crystal lattice interaction. This interaction may occlude access of ligands to the active site in crystal-soaking experiments, thereby impeding the determination of protein-fragment complex crystals; indeed, our efforts to use this crystal form for fragmentsoaking experiments did not result in any protein-fragment structures (data not shown). To break this salt bridge, we replaced a single amino acid (Glu82) with a residue commonly found at this position in closely related enzymes and obtained crystals in a new space group with altered crystal packing and increased solvent-channel access to the target site. This variant of PaDsbA1 is biochemically and structurally very similar to wild-type PaDsbA1, with conformational changes confined to the N-terminal end of helix 3. Furthermore, structures of the PaDsbA1 variant were determined in complex with multiple small molecules bound on its active-site surface, one from the crystallization condition and two from cryoprotectant solutions, providing proof of principle that in the new crystal form the active-site face is accessible to compounds introduced via soaking or co-crystallization.
Methods

Expression-vector construction
The P. aeruginosa dsbA gene lacking a signal sequence was previously inserted into a modified pET-28a plasmid (Novagen) to generate a construct with a Tobacco etch virus (TEV) protease-cleavable N-terminal His 6 tag (Shouldice et al., 2010) .
Site-directed mutagenesis
Glu82 of PaDsbA1 forms an ionic interaction with an active-site residue in the reported crystal structure. The amino-acid sequence of PaDsbA1 (UniProt ID P0C2B2) was aligned with homologues from E. coli, Klebsiella pneumoniae and Vibrio cholerae using ClustalW2 to identify residues to replace Glu82. Inspection of the resulting alignment identified that hydrophobic aliphatic side chains (Ile and Met) were found at positions equivalent to Glu82 of PaDsbA1. Subsequently, a single point mutation (Glu82 to Ile, hereafter referred to as E82I PaDsbA1) was introduced using a sitedirected mutagenesis approach. Two complementary primers (5 0 -CAG ATG TTT CTG ACA CTG ATA AGT ATG GGC  GTA GAA C-3  0 and 5  0 -GTT CTA CGC CCA TAC TTA TCA  GTG TCA GAA ACA TCT G-3 0 ) containing the desired isoleucine mutation and designed to anneal to opposite strands of the template vector were synthesized (GeneWorks, Australia). A 25 ml reaction containing 10 ng double-stranded parental vector, 5 mM of each primer, 1 mM dNTP and 0.5 ml PfuTurbo DNA polymerase (Pacific Laboratory Products, Australia) was subjected to 25 thermal cycles (95 C for 50 s, 56 C for 60 s and 68 C for 9 min) with a final extension of 10 min at 68 C. The parental vector was subsequently digested with 20 units of DpnI (New England BioLabs) at 37 C for 1 h and the resulting product was used to transform competent TOP10 E. coli cells. The introduced mutation was confirmed by sequencing (Australian Genome Research Facility, Australia).
Protein expression and purification
Wild-type (WT) PaDsbA1 (212 amino acids, 23.7 kDa) and E82I PaDsbA1 (212 amino acids, 23.7 kDa) were expressed and purified largely as described in Shouldice et al. (2010) , but with some modifications. Expression was performed in E. coli BL21 (DE3) pLysS cells at 30 C and 200 rev min À1 for 18 h in ZYP-5052 autoinduction medium [10%(w/v) tryptone, 5%(w/v) yeast extract, 0.5%(v/v) glycerol, 0.05%(w/v) glucose, 0.2%(w/v) -lactose, 25 mM ammonium sulfate, 50 mM KH 2 PO 4 , 50 mM Na 2 HPO 4 , 1 mM magnesium sulfate and trace metals] in the presence of ampicillin (100 mg ml À1 ) and chloramphenicol (34 mg ml
À1
). Harvested cells were resuspended in a solution consisting of 25 mM Tris pH 7.5, 150 mM NaCl, DNAse (Roche Diagnostics, Australia) and protease inhibitors (BioPioneer Inc., California, USA) and were lysed using a Constant Systems Cell Disrupter (single passage at 124 MPa pressure), and the soluble cell fraction was isolated by centrifugation (40 000g for 30 min). Immobilized metal-affinity chromatography (IMAC) purification was performed in batch using TALON resin (Clontech) equilibrated in 25 mM HEPES pH 7.4, 150 mM NaCl, 2 mM imidazole. Following wash steps (25 mM HEPES pH 7.4, 500 mM NaCl, 10 mM imidazole), purified protein was eluted with 25 mM HEPES pH 7.4, 150 mM NaCl, 200 mM imidazole. Purified protein was buffer-exchanged on a Sepharose gel-filtration column to remove imidazole prior to cleavage of the N-terminal His 6 tag by treatment with His-tagged TEV protease at a mass ratio of 1:100 enzyme:substrate. Contaminating TEV protease and uncleaved PaDsbA1 were removed by a second IMAC step. Purified tag-free PaDsbA1 (192 amino acids, 21.3 kDa for both WT and E82I PaDsbA1) was oxidized with a 50:1 molar excess of oxidized glutathione (Sigma-Aldrich). Finally, protein monodispersity and purity (>95%) were confirmed by size-exclusion chromatography (Superdex 75 16/60, GE Healthcare Life Sciences) and SDS-PAGE analysis, respectively. The protein oxidation state was confirmed by an Ellman assay (Ellman et al., 1961) .
Screening, optimization and routine production of E82I PaDsbA1 crystals
For all experiments, E82I PaDsbA1 was crystallized using the UQ ROCX Facility, the vapour-diffusion method and hanging drops. 96-well plates (100 nl protein solution and 100 nl reservoir solution equilibrated against 75 ml reservoir solution) were set up using a Mosquito crystallization robot (TTP Labtech) against commercially available crystallization screens or bespoke crystallization formulations prepared using a Tecan liquid-handling robot and the RockMaker software (Formulatrix). All crystallization experiments were maintained at 20 C. 
X-ray data collection
To cryocool the crystals, cryoprotectant solutions were prepared from stock solutions such that they matched the concentration of the mother-liquor components with the addition of either 40% polyethylene glycol 400, 20% ethylene glycol or 20% glycerol. In each case, crystals were briefly (<30 s) soaked in the respective cryoprotectant solution prior to plunging them into liquid nitrogen. X-ray data were collected at 100 K on the microfocus beamline MX2 at the Australian Synchrotron using an ADSC Quantum 315r detector. Data were collected at a wavelength of 0.95370 Å over a total angular rotation of 180 using 1 ' slices with an exposure time of 1 s. The data were indexed and integrated with iMosflm (Battye et al., 2011) and scaled using POINTLESS and SCALA or AIMLESS (Evans, 2006 (Evans, , 2011 Evans & Murshudov, 2013) within the CCP4 suite (Winn et al., 2011) . For crystals 1 and 2, all collected data were used and no limit on resolution was imposed during processing. For crystal 3, a resolution limit of 1.7 Å was imposed to maintain a mean I/(I) in the highest resolution shell close to 2.
Structure determination and refinement
All phasing and model-refinement procedures were implemented within the PHENIX software suite. The data were phased using molecular-replacement methods with AutoMR (6746) 132345 (18730) 72341 (10588 Table 2 Refinement and model quality.
Values in parentheses are for the highest resolution shell. atoms were refined with anisotropic atomic displacement parameters. Coordinates and restraints for PEG 400, ethylene glycol, glycerol and MES molecules were generated using elBOW (Moriarty et al., 2009 ) and the quality of the final model was assessed with MolProbity (Chen et al., 2010 ) throughout the refinement process. Data-collection and refinement statistics are summarized in Tables 1 and 2 . The final refined structures have been deposited in the Protein Data Bank (PDB entries 4zl7, 4zl8 and 4zl9). All structural figures were generated using PyMOL (v.1.6; Schrö dinger; http://pymol.org) and Adobe Illustrator.
Redox potential determination
The redox potentials of WT and E82I PaDsbA1 were determined fluorometrically by exploiting the redox-statedependent changes in the intrinsic fluorescence of a tryptophan residue close to the catalytic disulfide bridge. Oxidized PaDsbA1 samples were prepared by incubation with a molar excess of oxidized glutathione, which was subsequently removed using an NAP-5 desalting column (GE Healthcare). The redox state of the protein was confirmed by an Ellman assay (Ellman et al., 1961) . Oxidized PaDsbA1 (2 mM) in 100 mM sodium phosphate pH 7.0, 0.1 mM EDTA was combined with oxidized glutathione (1 mM) and a range of concentrations of reduced glutathione (4 mM to 100 mM) and allowed to equilibrate at 30 C overnight. The fraction of reduced and oxidized PaDsbA1 at equilibrium was determined from the relative fluorescence intensity of each reaction (excitation at 280 nm, emission at 340 nm) recorded in a black 96-well OptiPlate (PerkinElmer, Australia) using a Synergy H1 multimode plate reader (Biotek, Millennium Science, Australia). Six independent experiments were performed to determine the equilibrium constant with glutathione. The redox potential was calculated using the Nernst equation as described previously (Wunderlich & Glockshuber, 1993) .
Insulin reduction
The protein disulfide reductase activity of WT and E82I PaDsbA1 was measured in vitro using an insulin-reduction assay (Holmgren, 1979) . Briefly, in this reaction DsbA catalyzes the reduction (in the presence of DTT) of the intermolecular disulfide bonds between chains A and B of insulin. Upon reduction of the disulfide bonds, chain B precipitates, which can be detected as an increase in the optical density at 650 nm. Reaction solutions were prepared in a final volume of 200 ml in a 96-well transparent clear-bottomed plate and A 650 nm measurements were made at 15 s intervals over a period of 80 min on a Synergy H1 multimode plate reader (Biotek, Millennium Science, Australia). Reduced WT or E82I PaDsbA1 was prepared at a final concentration of 10 mM in 100 mM sodium phosphate pH 7.0, 2 mM EDTA, 0.3 mM DTT. Insulin (human insulin; Sigma-Aldrich) was added immediately prior to measurements at a final concentration of 0.131 mM.
Model peptide-substrate folding assay
The oxidase activity of WT and E82I PaDsbA1 was assayed using a peptide-oxidation assay, in which the steady-state Site-directed mutagenesis disrupts crystal packing involving active-site surface loops. (a) Sequence alignment of P. aeruginosa DsbA1 with homologues from E. coli, K. pneumoniae and V. cholerae to identify a suitable nonpolar amino-acid substitution for Glu82 in P. aeruginosa (marked with an asterisk). The figure was generated using ESPript3 (Robert & Gouet, 2014 fluorescence of a substrate peptide is directly coupled to its oxidation state. The substrate is dually labelled with a lanthanide metal ion (europium) and a sensitizer (methylcoumarin amide; MCA), which are spatially distant from one another in the reduced state but are in sufficiently close proximity to support efficient energy transfer in the oxidized state. Oxidation of the peptide substrate can be followed by measuring the fluorescence emission intensity of europium after specific MCA excitation. Accordingly, 80 nM WT or E82I PaDsbA1 in 50 mM MES pH 5.5, 50 mM NaCl, 2 mM EDTA was combined with 2 mM oxidized glutathione and 8 mM peptide substrate in a total volume of 50 ml. Oxidation of the peptide substrate was monitored in a Synergy H1 multimode plate reader using 384-well white OptiPlates (PerkinElmer, Australia) with excitation at 340 nm and emission at 615 nm, a 150 ms delay before reading and a 100 ms reading time.
3. Results and discussion 3.1. Protein engineering disrupts an active-site-mediated crystal-packing interaction
The active-site surface of DsbA enzymes is composed of a CXXC motif located at the N-terminal end of H1 in the thioredoxin domain and three additional loop regions (L1, linking 3 and H2; L2, linking H6 and 4 (the cis-Pro loop of the thioredoxin fold; Martin et al., 1993) ; and L3, linking 5 and H7, described in McMahon et al., 2014) , which together generate the redox-active site of the enzyme and form the surface for engagement with substrate and partner proteins.
Inspection of the crystal packing of the 1.5 Å resolution WT PaDsbA1 (Shouldice et al., 2010 ; PDB entry 3h93) crystal structure revealed that a number of intermolecular interactions engage the active-site surface in crystal lattice contacts; in particular, a salt bridge (2.88 Å ) between His39 of the active-site Cys-His-Pro-Cys motif and Glu82 of a symmetry-related mate and a hydrogen-bonding interaction (3.25 Å ) between the backbone N atom of Val153 (L3) and the carboxyl O atom of a Ser83 symmetry mate. Together, these result in a surface packing that may impede small-molecule access to the active site during crystal soaking experiments. Screening of alternative crystallization conditions using WT PaDsbA1 yielded crystals of different space groups (P4 and P4 1 with two molecules in the asymmetric unit) but did not break the primary His39-Glu82 sym crystal contact (data not shown).
To break the critical salt bridge, we employed site-directed mutagenesis, replacing Glu82 with isoleucine. We selected isoleucine for two reasons: firstly, its uncharged side chain cannot engage in electrostatic contacts and, secondly, isoleucine is found at this position in the closely related enzymes V. cholerae DsbA and K. pneumoniae DsbA (Fig. 1a) and substitution was therefore anticipated to have a minimal effect on both protein structure and function. We subsequently obtained crystals of the E82I PaDsbA1 variant in a new space group (P2 1 , one molecule in the asymmetric unit). The structure of the E82I PaDsbA1 variant (crystal 1) was determined to 1.9 Å resolution with an R factor of 15.9% (R free of 20.2%), indicating that the model represents the data with high accuracy. Details of data collection, solution methods and additional indicators of the quality of the final model are given in Tables 1 and 2 . Inspection of the structure confirmed that our site-directed mutagenesis approach successfully disrupted the previous intermolecular salt bridge. Calculation of the total surface area of interfacing surfaces involved in intermolecular crystal interactions using the Protein Interfaces, Surfaces and Assemblies service PISA at the European Bioinformatics Institute (http://www.ebi.ac.uk/ pdbe/prot_int/pistart.html) found that relative to WT PaDsbA1, E82I PaDsbA has a $20% reduction in its total crystal-packing interaction surface area (1238 Å 2 for WT PaDsbA1 compared with 1536 Å 2 for WT PaDsbA1; Krissinel & Henrick, 2007) . In the new packing configuration, no protein interactions are formed to His39 (Table 3) . Furthermore, relative to the WT PaDsbA1 crystals, fewer atoms of the active-site surface loops of the E82I PaDsbA1 variant are engaged in crystal contacts with protein molecules of neighbouring symmetry-related molecules (Figs. 1b and 1c, Table 3 ). Table 3 Number of active-site surface-loop residues involved in crystal-packing interactions in WT and E82I PaDsbA1 crystals.
Crystal contacts were identified using CONTACT within the CCP4 suite (Winn et al., 2011) 
positioning and conformation of the active-site surface loops is unaltered (Fig. 2a) . As a direct result of the engineered amino-acid substitution, the WT PaDsbA1 and E82I PaDsbA1 structures differ in the conformation of their H2-H3 connecting loop (Fig. 2) . Relative to WT PaDsbA1, a rearranged network of hydrogen bonding in E82I PaDsbA1 maintains the stabilization of particular H3 side chains but introduces both a kink and an additional partial helical turn to the N-terminal region of H3 (Figs. 2b and 2c) . Specifically, in WT PaDsbA1 Glu82 forms a side-chain-mediated hydrogen bond to the N "2 atom of the imidazole ring of His91. WT PaDsbA1 His91 is also involved in an additional side-chain contact (via its N 1 atom) to the hydroxyl group of the neighbouring Tyr35 (Fig. 2d) . In E82I PaDsbA1, where the nonpolar aliphatic Ile side chain replaces Glu82, this Glu82-specific stabilization of His91 is lost, and His91 is instead stabilized by side-chain-mediated hydrogen bonds to Glu44 and Glu87 (Fig. 2e) . Furthermore, the side chain of His91 is flipped relative to its orientation in the wildtype protein (Figs. 2d and 2e) . Glu44 is similarly positioned in both proteins, but in contrast Glu87 undergoes a significant repositioning in the E82I PaDsbA1 variant to mediate contact with His91; in this new orientation Glu87 is also suitably positioned to recapitulate a hydrogen bond to the Tyr35 hydroxyl group previously mediated by His91 N 1 . The overall effect of this altered hydrogen-bond network and the repositioning of Glu87 ( boundary of a groove on the posterior face of PaDsbA1 (Shouldice et al., 2010) ; comparison of WT and E82I PaDsbA1 indicate that the posterior groove of both proteins is essentially unchanged.
E82I PaDsbA1 exhibits wild-type protein activity and redox character
DsbA proteins catalyze the oxidation of the thiol groups of cysteine residues to form stabilizing disulfide bonds. We measured the redox properties of the E82I PaDsbA1 variant and compared them with those of WT PaDsbA1 to determine whether or not the introduced mutation altered the ability of the protein to catalyze disulfide formation. Crucially, the E82I substitution does not affect protein function or redox character (Fig. 3) . E82I PaDsbA1 has essentially identical activity to WT PaDsbA1 in both an in vitro peptide substrate oxidation assay (Fig. 3a) and a classical insulin-reduction assay (Fig. 3b) . The E82I PaDsbA1 redox potential is unchanged [K eq with glutathione of 1.19 AE 0.11 Â 10 À5 M (Fig. 3c ) relative to 9.96 AE 0.88 Â10 À6 M for WT PaDsbA]. This equates to redox potentials of À92 and À94 mV, respectively.
Crystal structures of E82I PaDsbA1 with three cryoprotectants
During the initial characterization of the E82I PaDsbA1 variant crystals, we explored a number of cryoprotectants to identify which was optimal for crystal cryocooling. In all, we determined the crystal structures of E82I PaDsbA1 cryoprotected with 40% PEG 400 (crystal 1, Table 1 , PDB entry 4zl7), 20% glycerol (crystal 2, Table 1 , PDB entry 4zl8) and 20% ethylene glycol (crystal 3, Table 1 , PDB entry 4zl9). All three structures were determined at high resolution (in the range 1.4-1.9 Å ) and were of comparable quality, although we note that the glycerol-cryoprotected crystals yielded the highest resolution diffraction data (Table 1) .
3.4.1. E82I PaDsbA1 can bind PEG molecules on its noncatalytic surface. A molecule of hexaethylene glycol (polyethylene glycol, PEG 400), which was used as a cryoprotectant during crystal cryocooling, is found in the electrondensity map of E82I PaDsbA1 crystal 1. PEG 400 is bound at the C-terminal end of H1 (Fig. 4a) . The molecule adopts a horseshoe configuration encircling the side chain of Lys53 (Fig. 4b) . Electron density is sharply resolved for the majority of the molecule, where it is in closest proximity to Lys53, but is poorly resolved for the first two ethylene glycol monomer units of the molecule (Fig. 4b) ; accordingly, atoms O1-C5 inclusive have elevated B factors with respect to the rest of the non-H atoms of the bound PEG 400. Two O atoms of PEG 400 make hydrogen-bonded contacts to Lys53 NZ: O10 and O16 Figure 3 E82I PaDsbA1 exhibits wild-type protein activity and redox character. (a) WT and E82I PaDsbA1, in the presence of 2 mM oxidized glutathione, display a similar rate of oxidation of a fluorescently labelled peptide substrate. Reactions lacking glutathione, a protein catalyst or containing only buffer display negligible activity. The mean and SEM of four (WT) and three (E82I) independent biological replicates are plotted. For GSSG and buffer-only controls n = 1. (b) The disulfide reductase activity of WT and E82I PaDsbA1 was assessed using an insulin-reduction assay. WT (blue) and E82I (orange) PaDsbA1 catalyze the reduction of insulin in the presence of DTT to a similar extent. The mean and SEM of three independent biological replicates are plotted. (c) The fraction of oxidized and reduced E82I PaDsbA1 after equilibrium in redox buffers containing varying ratios of reduced glutathione:oxidized glutathione at pH 7.0 and 310 K was determined from the redox state-dependent fluorescence of PaDsbA1. These data were used to calculate K eq and subsequently the redox potential. Representative data of a single experiment of six performed are shown, plotted on a semi-log graph using a base 10 logarithmic scale for the x axis and a linear scale for the y axis. For final redox potential determination, mean and SEM were calculated (n = 6).
(distances of 2.87 and 3.05 Å , respectively). PEG 400 makes additional contacts to Pro49, Trp50, Leu54 and Pro55 of H1 and Asp180 of H7.
We note that PEG 400 binds in a similar vicinity to that of a glycerol molecule (Glyc-3) resolved in the structure of WT PaDsbA1 (Shouldice et al., 2010) ; in this structure Glyc-3 is positioned towards the C-terminal end of H1 between H1 and H7 within hydrogen-bonding distance of the side chains of H7 residues Asp180 and Arg187. As noted previously, this area is rich in acidic and basic residues (Shouldice et al., 2010) , and in crystal 3 (current study) a further PEG molecule from the crystallization condition can also be resolved near Asp187 and Glu184 of H7.
3.4.2. E82I PaDsbA1 binds several small molecules at its active site. E82I PaDsbA1 can also bind several small molecules directly on the catalytic face of the protein. In the crystal structures of the E82I PaDsbA1 variant cryocooled with either glycerol (crystal 2) or ethylene glycol (crystal 3), His39 in the active site makes electrostatic and hydrogen-bond contacts with a molecule of the respective cryoprotectant and also a molecule of 2-(N-morpholino)ethanesulfonic acid (MES). MES, which is presumably derived from the crystallization condition common to all three crystals, is not resolved in crystal 1, where His39 makes no apparent contacts to a component of the mother liquor or cryoprotectant.
In crystals 2 and 3, the orientation of the His39 imidazole ring is rotated relative to its position in the WT PaDsbA1 and PEG 400 cryocooled structures (crystal 1, present work; depending on the crystal form and the protein redox state (Guddat et al., 1998) . We suggest that in this case the observed reorientation of His39 is a direct consequence of glycerol or ethylene glycol binding, and that this in turn brings His39 into an orientation that is permissive for a stable interaction with MES.
The bound molecules of MES and cryoprotectant (glycerol or ethylene glycol) are each involved in numerous side-chainmediated and main-chain-mediated hydrogen-bond interactions with residues of the active-site surface loops (CPHC loop, cis-Pro L2 and L3; Fig. 6 ). In crystal 2, three molecules (two glycerols and one MES) decorate the active-site loops, variously contacting Cys37, Pro38 and His39 (CPHC), Thr151, Gly152 and Val163 (cisPro L2), and Ile166 and Gly167 (L3) (Figs. 6b, 6c and 6d) . Together, this provides a serendipitous proof of principle that in the engineered E82I PaDsbA1 variant the active site is available to small molecules that are both present during crystallization (i.e. MES) and introduced via soaking (i.e. cryoprotectant glycerol).
Conclusion
P. aeruginosa is a common cause of hospital-acquired infections (Rosenthal et al., 2012) . In the USA, 13% of severe nosocomial P. aeruginosa infections are multidrug-resistant, meaning that all or nearly all currently available antibiotics are ineffective as treatments (Centers for Disease Control and Prevention, 2013) . 'Prompt and sustained action' including the development of new drugs is required to counter, and prevent the escalation of, the threat to public health (Centers for Disease Control and Prevention, 2013) . DsbA is essential for multiple facets of P. aeruginosa virulence and is a highly promising target for new drug development. DsbA inhibitors would disrupt bacterial virulence rather than growth, serving as potent anti-infectives whilst exerting a reduced selection pressure to develop resistance (Heras et al., 2015) .
WT PaDsbA1 did not give crystals that were amenable for use in a fragment-screening approach. Here, we have generated a variant of PaDsbA1 to disrupt an active-site residuemediated crystal contact. Whilst there are localized conformational changes to the N-terminal end of H3 of the variant protein E82I PaDsbA1, the active-site surface of the protein (CPHC, L1, cis-Pro L2 and L3) is unchanged, and crucially the protein activity and redox character are essentially identical to those of the wild type. In the identified crystal form of E82I PaDsbA1, the active-site region can simultaneously bind multiple ligands derived from the crystallization condition and cryoprotectant solution, indicating that the new crystal form is suitable for use in subsequent FBLD campaigns to characterize small-molecule binders of this important mediator of bacterial virulence.
In the early stages of fragment-based lead discovery campaigns, hit fragments typically exhibit low-affinity binding to their target. This presents an inherent challenge to obtaining protein-fragment crystal structures, in which a high occupancy of fragment in the crystal at the binding site is essential to resolve the corresponding electron density. It follows that to maximize the chances of successful soaking experiments one should avoid the potential for competition from other molecules that may also bind at the target site in the crystal. For this reason, we suggest that crystal 1 is the most suitable for subsequent structural and fragment-based lead discovery experiments, as either glycerol or ethylene glycol may directly or indirectly compete for fragment binding in this region.
